Fri, Sep 19, 2014, 2:14 AM EDT - U.S. Markets open in 7 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Jul 19, 2011 7:17 AM Flag

    catmanzeke.....here

    catman, I did find another example where TB 4 was used in human compassionate use IND....and there was doxycycline too. But some not. Here are the case studies of four such patients and TB 4, with eye ulcers that were not healing with any other regimine, and had been that was for a few months. TB 4 was a 75% winner.:

    "Case 1:: An 81-year-old white man with a 12-year history of diabetes subsequently developed HZO in the right eye with decreased corneal sensation. A persistent right corneal epithelial defect of 11 weeks' duration developed and was unresponsive to treatment that included nonpreserved lubricants, Vigamox (Alcon, Fort Worth, Texas), and a bandage contact lens. His epithelial defect measured 2.0 x 1.0 mm at the start of treatment with 2 drops 4 times daily of thymosin beta 4 for 4 weeks. Treatment with Vigamox 4 times daily and preservative-free tears were continued. The defect was healed on day 25 and remained so during the 30-day follow-up period (Table, Figure 1, and Figure 2).

    Case 2 :: A 47-year-old white woman with a 23-year history of diabetes and associated peripheral neuropathy and retinopathy developed a persistent right corneal epithelial defect of 6 weeks' duration that was unresponsive to treatment including nonpreserved lubricants, Vigamox, and a bandage contact lens. Corneal sensation was decreased. Her epithelial defect measured 3.5 x 3.0 mm prior to treatment with 2 drops 4 times daily of thymosin beta 4 for 4 weeks. Treatment with Vigamox twice daily and erythromycin ophthalmic ointment were continued. On cessation of thymosin beta 4 treatment the defect measured 1.0 x 0.25 mm. At the termination of follow-up (week 8), a sliverlike defect remained that measured 1.5 x 0.2 mm (Table and Figure 2).

    Case 3 ::An 84-year-old white man with a history of HZO in the left eye developed a persistent left corneal epithelial defect of 14 months' duration that was unresponsive to treatment including nonpreserved lubricants, erythromycin ophthalmic ointment, and a bandage contact lens. Corneal sensation was absent. His epithelial defect measured 1.0 x 0.5 mm prior to treatment with 2 drops 4 times daily of thymosin beta 4 for 4 weeks. Use of erythromycin ophthalmic ointment was continued. On cessation of thymosin beta 4 treatment, the defect measured 1.1 x 0.5 mm. At the termination of follow-up (day 70), a fine healing line was present (Table and Figure 2).

    Case 4 ::A 57-year-old white man with a 10-year history of diabetes subsequently developed HZO in the right eye with an anesthetic cornea. He developed a persistent left corneal epithelial defect of 12 weeks' duration that was unresponsive to treatment including nonpreserved lubricants, topical antibiotics, oral doxycycline, and a bandage contact lens. His epithelial defect measured 4.5 x 2.8 mm at the start of treatment with 2 drops 4 times daily of thymosin beta 4 for 4 weeks. Treatment with erythromycin ophthalmic ointment and oral doxycycline were continued. One drop of prednisolone acetate, 1%, with benzalkonium chloride, 0.01%, preservative was continued to maintain control of a smoldering uveitis. On cessation of thymosin beta 4 treatment, the defect measured 0.8 x 0.3 mm. The defect was healed on day 42 and remained that way through the remainder of the follow-up period (day 56) (Table and Figure 2).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • catman....Hre's the other compassionate use trial results. I couldn'r find them before I know it is not that many pts, but the results were fabulous. Far better than RESTASIS getting approved with on;y 15% response rate for dry eye. In this Compassionate USe study, the patients had bad eye ulcers which woudl not heal with anything.

      TB 4 got a 66% cure rate in the NK pts.... and a about 60% response rate for overall both.

      <<In the second compassionate use study, a corneal specialist treated nine patients divided into two groups. The first group consisted of six patients with a single non-healing eye ulcer resulting from neurotrophic keratitis, or NK, a rare degenerative corneal disease commonly caused by the herpes zoster virus and induced by a nerve impairment resulting in painful corneal lesions that can lead to blindness. The NK patients evaluated had defects that had not healed for at least six weeks and in some cases for several years. The second group consisted of three patients with diffuse punctate erosions, corneal defects that appear as numerous small pinhole-sized lesions.

      All nine patients were treated with RGN-259 for periods of up to 49 days. The six NK patients with single non-healing ulcers showed clinically significant improvement during the treatment with RGN-259 and the follow-up period, with four of the six patients healing completely. The completely healed ulcers remained healed during the follow-up period, and those that had demonstrated significant improvement continued to improve after completion of treatment with RGN-259. The three patients with diffuse punctate erosions demonstrated no significant improvement, although they did report reduced ocular irritation.

 
RGRX
0.1369+0.0047(+3.56%)Sep 18 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT